Novartis’ Cosentyx (secukinumab) has failed to show any benefit in the Phase III study in adults with newly diagnosed or ...

Novartis announced top-line results from the phase III GCAptAIN study evaluating Cosentyx (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the study, Cosentyx ...

Eli Lilly has struck a $2.4 billion deal to buy Dice Therapeutics and its drug discovery and development platform for oral, small molecule therapies for immunological diseases. Th ...